GlycoMimetics scales down IPO to $46M; Isarna raises $18M for cancer R&D; Aldexa files $20M IPO;

@FierceBiotech: Texas' Bellicum gets $15M to expand work on gene 'switch' tech. More | Follow @FierceBiotech

@JohnCFierce: In search for success, R&D teams are overcrowding small drug franchises. Story | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: Alcohol-addicted rats treated with optogenetics stop drinking. More from FierceBiotech Research | Follow @EmilyMFierce

> In a renewed effort to go public, GlycoMimetics says it will sell 5.8 million shares at $8 each. The IPO is now designed to raise about $46 million. Story

> Germany's Isarna Therapeutics has raised close to $18 million in venture cash. The biotech says it plans to use the money on its "pipeline of next generation oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation." Release

> Burlington, MA-based Aldexa Therapeutics filed for a $20 million IPO. The biotech is studying new therapies for rare diseases. Filing

Medical Device News

@FierceMedDev: BD trades $40M for diagnostics partner Alverix. More | Follow @FierceMedDev

@MichaelGFierce: How a single nanoparticle delivers two drugs separately to kill cancer cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: The FDA warns Abbott's faulty blood glucose test strips could lead to serious injury or death. Story | Follow @GalenMoore

> Sapheon hauls in $10M as it works toward FDA approval for a varicose vein device. Item

> Stryker teams with Samsung's NeuroLogica on a portable CT scanner. More

> FDA slaps its most serious label on Abbott's diabetes recall. Article

> Medtronic spends $160M on Tyrx and its antibacterial envelopes. News

Pharma News

@FiercePharma: Move over, BigPharma. Valeant's CEO plans to elbow his way in. More | Follow @FiercePharma

@EricPFierce: China clears vaccinemakers in deaths then shuts some down. Story | Follow @EricPFierce

@CarlyHFierce: Hi-Tech Pharmacal CEO to reap almost $85M from its sale to Akorn. Article | Follow @CarlyHFierce

> Just as hep C star Sovaldi makes its debut, Gilead commercial chief says he'll retire. More

> Lilly admits 2014 sales won't hit $20B, but sticks to $3B profits target. News

Biotech Research News

> Cancer Research UK will repurpose an AstraZeneca asthma drug for kidney cancer. More

> 6 U.S. institutions receive $540M in cancer research funds. Story

> Astellas, ClearPath team up to develop vaccines for infectious diseases. Article

> Gene defect that blocks insulin release in mice may cause Type 2 diabetes. News

> Alcohol-addicted rats treated with optogenetics stop drinking. Report

> Discovery of immune boosters' role in TB control could help develop new therapeutics. Item

Pharma Manufacturing News

> $1B deal pushes GE further into biologics manufacturing. More

> Pall moves into single-use bioreactors with deal to buy ATMI LifeSciences. Article

> Chinese heparin maker Hepalink buying U.S.-based SPL. Story

> China clears vaccine makers in deaths then shuts some down. News

> EMA makes inspection reports public. Item

> Baxter issues another recall after particulate found in products. Report

 

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.